STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRML
  4. [EFFECT] Tourmaline Bio, Inc. SEC Filing

[EFFECT] Tourmaline Bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 14, 2025
Accession Number: 0001104659-25-102981
Submission Type: POS AM
CIK: 0001827506
Company Name: Tourmaline Bio, Inc.
File Number: 333-283078

Source: View Original Filing on SEC EDGAR

Stock TRML logo
Tourmaline Bio

NASDAQ:TRML

TRML Rankings

#2596 Ranked by Market Cap
N/A Ranked by Dividends

TRML Latest News

Sep 9, 2025
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
Aug 31, 2025
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
Aug 13, 2025
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
May 20, 2025
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
May 19, 2025
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

TRML Latest SEC Filings

Oct 28, 2025
[Form 4] Tourmaline Bio, Inc. Insider Trading Activity
Oct 28, 2025
[Form 4] Tourmaline Bio, Inc. Insider Trading Activity
Oct 28, 2025
[Form 4] Tourmaline Bio, Inc. Insider Trading Activity
Oct 28, 2025
[Form 4] Tourmaline Bio, Inc. Insider Trading Activity
Oct 28, 2025
[Form 4] Tourmaline Bio, Inc. Insider Trading Activity

TRML Stock Data

1.23B
21.70M
22.06%
89.92%
10.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK